DOES LIGHT CHAIN SUPPRESSION THERAPY IMPROVE CARDIAC STRUCTURE AND FUNCTION IN PATIENTS WITH ADVANCED AL AMYLOIDOSIS

Cardiac dysfunction is the major determinant of survival in patients with advanced light chain (AL) amyloidosis. Whether monoclonal light chain suppression therapy, the mainstay of AL amyloidosis, can improve cardiac function remains uncertain. 94 patients with newly diagnosed AL amyloidosis from